Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘bempegaldeskin’

In honour of Armistice / Veteran’s Day 11/11

National Harbor – We’re continuing our SITC 2019 coverage with a look at some intriguing and likely controversial data.

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15 (more on that tomorrrow)

But…

Nektar’s pegylated IL–2, bempeg, in combination with nivolumab in frontline metastatic melanoma.

The controversy will no doubt continue to rage with fervent fans and equally intense deniers, but what can we learn from the latest data that was presented by Dr Adi Diab and where are things likely headed?

Included in this latest update are an in-depth thought provoking expert interview with Nektar’s Dr Jonathan ‘JZ’ Zalevsky, plus commentary and analysis on what this all means when we look at the bigger strategic picture.

To learn more from our oncology coverage and get a heads up on our latest insights from the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

NKTR-214 Cover on Cancer Discovery

In the third part of our mini-series on cytokines, we get down and dirty with another pegylated IL-2 approach, this time from Nektar Therapeutics, including an interview with the PI, Dr Adi Diab from MD Anderson Cancer Centre and CSO, Dr Jonathan Zalevsky.

We’ve certainly had many full ranging discussions and chats with the good gentlemen; here we continue our journey to understand more about the science and underlying biology, as well as key biomarkers of response.

We can also be provocative too and put them on the spot regarding their critics and some of the pointed questions that get bandied about, which certainly makes for interesting reading.  Are they justified?

What should we be looking for when analysing the data?  You can find out for yourselves in the latest expert interview.

Other pertinent topics are also covered including where they’re headed and future data readouts to expect.

To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!